WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory agency for the United Kingdom, has granted a product license for the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience, Inc.

Ethyol is a selective cytoprotective agent indicated for the reduction of neutropenia-related infection resulting from use of the combination of cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol) in patients with advanced ovarian carcinoma.

Approval of ethyol in this country suffered a set back when an advisory committee failed to recommend it to the FDA.